Advanced oxidation protein product level in children with chronic otitis media with effusion.
OBJECTIVE
To determine the level of advanced oxidation protein products (AOPPs) in children with chronic otitis media with effusion (COME), in an effort to elucidate the multifactorial etiology of this disease.


METHODS
This study involved 25 COME patients and 30 healthy children (control group) recruited from the Ear, Nose and Throat (ENT) and Pediatric Departments, respectively, of the Haseki Research and Training Hospital. In the COME group, blood samples were collected before a middle ear operation, and middle ear fluid was sampled during the operation. Blood samples were also obtained from the control subjects. AOPP levels in the plasma and effusion fluid were measured by the spectrophotometric method.


RESULTS
In the COME group, the mean AOPP levels in plasma and effusion fluid were 168.08 μmol/l and 412.75 μmol/l, respectively. In the control group, the mean plasma AOPP level was 141.54 μmol/l. The plasma AOPP levels did not significantly differ between the COME and control groups (p>0.05). In the COME group, however, the effusion fluid AOPP level (412.75 ± 204.54 μmol/l) was significantly higher than the plasma AOPP level (168.08 ± 68.45 μmol/l; p<0.01).


CONCLUSIONS
We found that AOPP levels were elevated in the effusion fluid, but not in the plasma, of COME patients. Thus, COME was associated with protein oxidation abnormalities. Oxidative stress may play a role in the etiopathogenesis of COME, and AOPPs may be used as markers of oxidative stress; however, further studies are required to confirm these findings.
Department of Otorhinolaryngology, Susehri Government Hospital, Sivas, Turkey. Electronic address: balikcient@gmail.com.
Hasan Huseyin
HH
Balıkcı
Department of Otorhinolaryngology, Haseki Research and Training Hospital, Istanbul, Turkey.
Mustafa
M
Karakaş
Department of Otorhinolaryngology, Uskudar Government Hospital, Istanbul, Turkey.
Muhammet Mustafa
MM
Gürdal
Department of Otorhinolaryngology, Haseki Research and Training Hospital, Istanbul, Turkey.
Murat Haluk
MH
Ozkul
Department of Otorhinolaryngology, Haseki Research and Training Hospital, Istanbul, Turkey.
Ozlem
O
Bayram
Department of Otorhinolaryngology, Haseki Research and Training Hospital, Istanbul, Turkey.
Ali Alper
AA
Bayram
Department of Biochemistry, Beysehir Government Hospital, Konya, Turkey.
Servet
S
Yigit
D062107:Advanced Oxidation Protein Products / Q000032:analysis / Q000378:metabolism*; D000975:Antioxidants / Q000627:therapeutic use; D015415:Biomarkers / Q000032:analysis / Q000378:metabolism; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008297:Male; D010034:Otitis Media with Effusion / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism*; D010084:Oxidation-Reduction; D018384:Oxidative Stress / Q000502:physiology; D011379:Prognosis; D012016:Reference Values; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index
D062107:Advanced Oxidation Protein Products; D000975:Antioxidants; D015415:Biomarkers
Advanced oxidation protein product (AOPP); Antioxidant; Chronic otitis media with effusion; Oxidative stress